Deanna L. Kirkpatrick

Davis Polk advised the joint book-running managers and representatives of the underwriters in connection with the $69 million follow-on offering of common stock of Magenta Therapeutics…

Davis Polk advised the joint book-running managers on an SEC-registered offering by Abbott Laboratories of $650 million aggregate principal amount of 1.150% notes due 2028 and $650…

Davis Polk advised the underwriters in connection with the initial public offering of 51,750,000 units of Trebia Acquisition Corp., including 6,750,000 units purchased pursuant to the…

Davis Polk advised the representatives of the underwriters in connection with the $230 million initial public offering of 12,105,263 shares of common stock of Generation Bio Co., which…

Davis Polk advised the lead managers on an SEC-registered offering by TD Bank of (i) $1.75 billion aggregate principal amount of its 0.750% senior notes due 2023 and (ii) $1 billion…

Davis Polk advised the placement agent in connection with a private placement pursuant to Rule 4(a)(2) by Humanigen Inc. of $72 million of common stock. Humanigen Inc. is a clinical…

Davis Polk advised the representatives of the several underwriters, in connection with the initial public offering of 103,500,000 units of Foley Trasimene Acquisition Corp., including…

Davis Polk advised the underwriters in connection with the offering of $1.75 billion aggregate principal amount of 1.050% bonds due May 21, 2027 issued by the Province of Ontario. The Davis…

Davis Polk advised the underwriters in connection with the offering of $1.15 billion aggregate principal amount of notes issued by Lockheed Martin Corporation. The notes were offered in two…

Davis Polk advised the underwriters in connection with the offering of $2.25 billion aggregate principal amount of 1.000% bonds due May 20, 2025, issued by the Province of Alberta. The…